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comparison of SFC versus MON in children with symptomatic asthma receiving 
inhaled corticosteroids and short-acting β2-agonists. Asthma-related medication, 
unscheduled physician contacts and hospitalizations were collected prospectively. The 
main effectiveness measure was percentage of asthma-controlled week with no short-
acting β2-agonist use during the study period. The analysis was conducted from the 
Mexican health care perspective using 2010 unit cost prices, and only direct costs were 
considered, all costs are reported in US dollar. The model was made fully probabilistic 
to reﬂ ect the joint uncertainty in the model parameters. RESULTS: Over the whole 
treatment period, the median percentages of asthma-controlled weeks were 83.3% in 
the SFC group and 66.7% in the MON group (SFC-MON difference, 16.7%; 95% 
CI, 8.3–16.7; P < 0.001 in favor of SFC). The mean total cost of the SFC regimen was 
US$186 compared with US$271 for the MON regimen. The SFC was the dominant 
strategy (both more effective and less expensive) using the SFC was associated with 
an incremental cost per additional asthma-controlled of $US (513). Probabilistic 
sensitivity analysis tested numerous assumptions about the model cost and efﬁ cacy 
parameters and found that the results were robust to most changes. CONCLUSIONS: 
This analysis demonstrates that, compared with MON, SFC may be cost saving from 
the Mexican health care perspective for the treatment of pediatric patients with 
asthma. SFC provided a reduction in the number of severe exacerbations, frequent 
asthma symptoms and rescue medication use. Incremental cost-effectiveness analysis 
indicated the dominance of SFC because of both lower costs and greater efﬁ cacy.
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OBJECTIVES: Clinical and economic evaluations of the same trial often use different 
statistical analyses and methods to handle missing data. This leads to different results 
for the same health outcome. We aimed to study how the combination of multiple 
imputation (MI) with frequently used advanced methods of clinical analysis affect 
estimates of cost-effectiveness. METHODS: Data from a two-year RCT of an INTER-
disciplinary COMmunity-based COPD management program (INTERCOM) versus 
usual care were used. Five outcomes, SGRQ, EQ-5D, 6MWD, total and severe exac-
erbations measured at 4, 12 and 24 months or continuously (exacerbations) were 
selected. These outcomes were re-analyzed using the same methods used in the clinical 
paper, i.e. with repeated measurement analysis or negative bionomial regression, but 
now after missing data have been imputed using MI. The resulting estimates were 
compared with 1) the estimates in the original clinical paper before MI and 2) the 
estimates obtained after MI based on simple averages before any further statistical 
analyses based on maximum likelihood. RESULTS: A total of 175 patients were 
included in the analysis of which 158 completed the trial. The cost difference of c2751 
between INTERCOM and usual care was kept constant. The number of severe exac-
erbations avoided varied from 0.014 to 0.077 resulting in ICERs from c35,700 to 
c196,500, depending on the approach used. The improvement in SGRQ ranged from 
2.2 to 2.6 units, but the ICERs were all around c1000. The gain in QALYs varied 
from 0.062 with an ICER of c44,400 to 0.085 with an ICER of c32,400 per QALY 
gained. The probability that the INTERCOM program was cost-effective at a thresh-
old value of c50,000 ranged from 56% to 74%. CONCLUSIONS: This study showed 
that the combination of analytic approaches of the clinical and economic evaluations 
does alter the cost-effectiveness ratios.
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OBJECTIVES: To assess cost-effectiveness of adding SAL/FP to routine COPD treat-
ment with Fen/IB. METHODS: Depersonalized patient database was created in mul-
ticenter observational research of severe and very severe COPD. Patients were 
subdivided into two groups: 1- Fen/IB-based therapy without SAL/FP (N = 245); 2- 
Fen/IB-based therapy with SAL/FP (N = 84). Prices of drugs were up to Q1 2010 for 
Moscow city (from Farmexpert market monitoring). Unit cost of inpatient-day, out-
patient-visit and emergency-visit was derived from Moscow city government regula-
tion #290 from 04.2010 (about medicare). Direct medical costs within one year time 
horizon were assessed as health care perspective was taken. RESULTS: Number of 
COPD exacerbations per patient was 3.9 with and 6.8 without SAL/FP. Sum of yearly 
direct medical costs was 31,607 RUB (c832) with and 55,179 RUB (c1452) without 
SAL/FP. Incremental cost per one prevented exacerbation (ICER) was 1237 RUB 
(c32.5). Average cost of treatment of one exacerbation was 8 056 RUB (c212). Results 
were sensitive to unit cost of inpatient-day (25% increase leads to cost-saving in with 
SAL/FP arm). Indirect cost inclusion lead to considerable cost-saving in with SAL/FP 
arm (7952 RUB = c209). CONCLUSIONS: Adding SAL/FP to routine treatment of 
severe and very severe COPD with Fen/IB is cost-effective.
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OBJECTIVES: To assess cost-effectiveness of SAL/FP vs. mono-ICS in different 
Russian regions using OPTIMA pharmacoeconomic model. METHODS: Description 
and calculation steps of OPTIMA model were published in ISPOR Twelfth Annual 
European Congress Research Abstract #PRS8. Variable region-speciﬁ c input data: 
drug prices and dosage proportion (from Farmexpert monitoring as of Q4 2009), 
medical tariffs (from regional government regulations), GDP per capita and average 
salary (from statistics service). Constant disease-speciﬁ c data: frequency of controlled/
uncontrolled asthma in arms (from clinical trial), number of unscheduled resources 
utilization and QoL in controlled and uncontrolled asthma (from prof. I.V.Demko’s 
observational study). Fixed combination SAL/FP (Seretide) was compared with mono-
ICS (Beclomethasone, Fluticasone and Budesonide). ICERs (cost per QALY) were 
assessed for each 84 Russian regions. Regional WTP was assumed as three regional 
GDP per capita. 1 EUR = 38 RUB. RESULTS: Weighted average monthly pharmaco-
therapy cost varied from 1410RUB (in Kostroma) to 3376RUB (in Tula) for SAL/FP, 
and from 430RUB (in Kostroma) to 1524RUB (in Khanty-Mansi) for MonoICS. The 
differences were driven by proportion of low/medium/high doses. Medical tariffs 
varied dramatically as well: tariffs of outpatient visit varied from 107RUB (in Ivanovo 
and Dagestan) to 975RUB (in Yamal-Nenets), bed-day cost varies from 500RUB (in 
Kurgan) to 3123RUB (in Yamal-Nenets). GDP per capita were from 38110RUB (in 
Ingush) to 928374RUB (in Tyumen); average salary—from 9 125 RUB (in Dagestan) 
to 46480RUB (in Yamal-Nenets). SAL/FP was cost-saving (dominating) in 18 regions, 
cost-effective in 62 regions (ICER < WTP; in this regions ICERs were from 3210RUB 
(84EUR) to 639480RUB (16828EUR) per QALY), and disadvantageous (ICER > 
WTP) in 4 regions (Ivanovo, Kabardino-Balkaria, Ingush, and Dagestan; mainly due 
to low WTP). CONCLUSIONS: In general case SAL/FP was cost-effective in most 
Russian regions, in some regions SAL/FP was cost-saving, and in few regions—not 
cost-effective. To assess cost-effectiveness in particular cohort of patients additional 
analyses are needed.
PRS33
ECONOMIC EVALUATION OF ILOPROST, EPOPROSTENOL AND 
TREPROSTINIL FOR THE TREATMENT OF PULMONARY ARTERIAL 
HYPERTENSION
Román A1, Barberà JA2, Escribano P3, Sala ML4, Febrer L5, Casado MA6
1Hospital de la Vall d’Hebron, Barcelona, Catalunya, Spain; 2Hospital Clínic de Barcelona, 
Barcelona, Catalunya, Spain; 3Hospital 12 de Octubre, Madrid, Spain; 4Hospital de la Santa 
Creu i Sant Pau, Barcelona, Catalunya, Spain; 5Bayer Healthcare, Barcelona, Catalunya, Spain; 
6Pharmacoeconomics & Outcomes Research Iberia, Pozuelo de Alarcón , Madrid, Spain
OBJECTIVES: To analyze the eﬁ ciency of three alternative treatments (inhaled ilo-
prost (ILO), intravenous epoprostenol (EPO) and subcutaneous treprostinil (TRE)) for 
patients suffering from pulmonary arterial hipertensión (PAH) iniciating therapy with 
a prostanoid. METHODS: A Markov model was built to simulate a PAH patient 
cohort in functional class III of the New York Heart Association (NYHA). The model 
had four health states, those of the functional classes, plus death. Treatment changes 
were allowed when patients worsened from class III to IV. Time horizon was three 
years and transition cycles were of 12 weeks. Perspective was that of the National 
Health System (NHS) in Spain. Data sources were: 1) literature review, 2) costs 
databases and 3) expert opinion. Costs were expressed in euros 2009. Costs and effects 
were discounted at a 3% rate following Spanish recommendations. Both, deterministic 
and probabilistic analyses were performed to check for robustness of results. 
RESULTS: At three years, results for initiating prostanoid therapy with ILO, EPO and 
TRE were, respectively: total cost—c143,092, c430,271 and c360,387 -; efﬁ -
cacy—2.695 LYG, 2.729 LYG and 2.690 LYG -; —1.737 QALY, 1.780 QALY and 
1.728 QALY -; mean cost per LYG—c53,092, c157,678 and c133,997; mean cost 
per QALY—c82,376, c241,667 and c208,595 -. Incremental cost-effectiveness ratios 
and cost-utility ratios of EPO vs. ILO were: >8.5Mc/LYG and >6.5Mc/QALY, and 
vs. TRE were: >1.5Mc/LYG y > 1.3 Mc/QALY, much above the usually accepted 
threshold in Spain of 30,000 c/LYG or QALY. ILO was dominant vs. TRE. Sensitivity 
analyses conﬁ rmed these results. CONCLUSIONS: Initiating prostanoid therapy in 
class III PAH patients with intravenous epoprostenol is slightly more efﬁ cacious than 
the alternatives. At a three-year time horizon, inhaled iloprost shows to be the less 
costly alternative for the NHS in Spain.
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OBJECTIVES: To investigate if easily accessible pre-screening of individuals at risk 
for COPD leads to a more accurate selection of patients for ordinary spirometry, 
thereby improving the incidence of pathological test results. METHODS: Primary care 
